Compile Data Set for Download or QSAR
maximum 50k data
Found 210 of ic50 for UniProtKB: P00747
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...)
Affinity DataIC50:  10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...)
Affinity DataIC50:  10nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290334(9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290336(10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290334(9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290336(10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290286(7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290309((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290314(10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290320(10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290324(4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290286(7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290309((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290314(10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290320(10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290324(4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290307((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290312(4-(Piperidin-4-yl)-10-[4-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290313(10-Phenyl-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290269(10-Bromo-4-(piperidin-4-yl)pyrimido[1,2-b]indazol-...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290329(10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290307((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290312(4-(Piperidin-4-yl)-10-[4-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290313(10-Phenyl-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290269(10-Bromo-4-(piperidin-4-yl)pyrimido[1,2-b]indazol-...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290329(10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290308((−)-trans-4-(2-Methylpiperidin-4-yl)-10-phen...)
Affinity DataIC50:  15nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290343(10-(1-Methyl-1H-pyrazol-5-yl)-4-(piperidin-4-yl)py...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290315(4-(Piperidin-4-yl)-10-(pyridin-3-yl)pyrimido[1,2-b...)
Affinity DataIC50:  15nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290262(10-Chloro-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...)
Affinity DataIC50:  15nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290328(10-Bromo-7-fluoro-4-(piperidin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  15nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290331(10-Bromo-9-methyl-4-(piperidin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  15nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290333(10-Isopropoxy-4-(piperidin-4-yl)pyrimido[1,2-b]ind...)
Affinity DataIC50:  15nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290335(10-(2,6-Difluorophenyl)-4-(piperidin-4-yl)pyrimido...)
Affinity DataIC50:  15nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290343(10-(1-Methyl-1H-pyrazol-5-yl)-4-(piperidin-4-yl)py...)
Affinity DataIC50:  15nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290308((−)-trans-4-(2-Methylpiperidin-4-yl)-10-phen...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290311(10-(4-Methoxyphenyl)-4-(piperidin-4-yl)pyrimido[1,...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290315(4-(Piperidin-4-yl)-10-(pyridin-3-yl)pyrimido[1,2-b...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290262(10-Chloro-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290328(10-Bromo-7-fluoro-4-(piperidin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290331(10-Bromo-9-methyl-4-(piperidin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290333(10-Isopropoxy-4-(piperidin-4-yl)pyrimido[1,2-b]ind...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290335(10-(2,6-Difluorophenyl)-4-(piperidin-4-yl)pyrimido...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290311(10-(4-Methoxyphenyl)-4-(piperidin-4-yl)pyrimido[1,...)
Affinity DataIC50:  15nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290316(4-(Piperidin-4-yl)-10-(pyridin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  16nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290332(10-Bromo-7-methyl-4-(piperidin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  16nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290338(10-Bromo-8-fluoro-4-(piperidin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  16nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290316(4-(Piperidin-4-yl)-10-(pyridin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  16nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290332(10-Bromo-7-methyl-4-(piperidin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  16nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290338(10-Bromo-8-fluoro-4-(piperidin-4-yl)pyrimido[1,2-b...)
Affinity DataIC50:  16nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 210 total ) | Next | Last >>
Jump to: